Association of Transcatheter Aortic Valve Replacement Reimbursement, New Technology Add-on Payment, and Procedure Volumes With Embolic Protection Device Use.

ABSTRACT:

Importance

In the setting of uncertain efficacy and additional, unreimbursed cost, use of an embolic protection device (EPD) during transcatheter aortic valve replacement (TAVR) has had variable uptake. The Centers for Medicare & Medicaid Services (CMS) instituted a new technology add-on payment to cover EPD use in October 2018.

Objective

To evaluate the association between CMS TAVR reimbursement rates and EPD use.

Design, setting, and participants

This cohort study used the Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry to identify patients who underwent TAVR between January 2018 and September 2019. Analysis took place between July 2020 and February 2022.

Main outcomes and measures

The association between EPD

SUBMITTER: Lowenstern A 

PROVIDER: S-EPMC9386613 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature